HotSpot Therapeutics, Inc., a Boston-based biotechnology company, announced on Wednesday that it is presenting its initial clinical data from the monotherapy dose-escalation portion of the Phase one study of HST-1011 in a Proffered Paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, scheduled from 13 September to 17 September 2024, in Barcelona, Spain.
HST-1011 is an oral and selective inhibitor of Casitas B-lineage lymphoma proto-oncogene (CBL-B).
The clinical data is being revealed with a focus on safety, exposure, and pharmacodynamic measures.
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Telix Pharmaceuticals' TLX101 glioma therapy candidate shows promising efficacy
FluoGuide begins phase II trial of FG001 for head and neck cancer
Intas and Accord BioPharma complete acquisition of UDENYCA (pegfilgrastim-cbqv) business
Sumitomo Pharma America signs research and development agreement with NCI
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial
EDX Medical launches new testicular cancer detection test in UK
Oncolytics Biotech signs share purchase agreement with Alumni Capital
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
MaaT Pharma receives positive DSMB safety recommendation for Phase 2b trial of MaaT033